Model Medicines | AI-First Biotechnology Company

Precision Medicines, Broad Application

AI is the amplifier. Biology is the strategy. Assets are the validation.

2

Programs

2

Lead Assets

30+

Indications

2

Programs

2

Lead Assets

30+

Indications

Ask AI About Model Medicines

ModelMedicinesisanAI-firstbiotechnologycompanyengineeringfirst-in-classsmallmoleculesthattargetthebiologicallinchpinsunderlyingdisease

Platform

End-To-End AI Engine

Explore Platform

Design

We utilize an advanced AI driven end-to-end engine to precisely design drug franchise programs.

Design

We utilize an advanced AI driven end-to-end engine to precisely design drug franchise programs.

Discovery

Our target discovery models efficiently identify biological choke points central to multiple diseases.

Discovery

Our target discovery models efficiently identify biological choke points central to multiple diseases.

Development

We rapidly advance these validated pipeline-in-a-pill assets through preclinical development stages.

Development

We rapidly advance these validated pipeline-in-a-pill assets through preclinical development stages.

Programs

Biological Choke Points

RDRP Thumb-1

BRD4

Viral Replication

RdRp Thumb-1

A cryptic allosteric pocket on viral RNA-dependent RNA polymerase, conserved across single-stranded RNA virus families.

Explore RdRp T1

Transcriptional Control

BRD4

A transcriptional master regulator at the center of super-enhancer biology, conserved across oncology, fibrosis, immunology, and cardiovascular disease.

Explore BRD4

Pipeline

Pipeline-in-a-Pill

Explore Pipeline

MDL-001

MDL-4102

MDL-001

MDL-4102

MDL-001

MDL-4102

Partnership

Scientifically Validated by World-Class Research Institutes

Connect

Adolfo Garcia-Sastre, Ph.D
"A game-changer in the global fight against COVID-19."
Launa Aspeslet, Ph.D
"Model Medicines is one of the few companies that have achieved both platform and therapeutic success."
Davey Smith, MD, MAS, FACP, FIDSA
"We need a pan-antiviral drug like MDL-001 to protect ourselves and our communities from the triple threat of RSV, flu, and COVID-19."
Philippe A. Gallay, Ph.D
"There has never been an orally available antiviral that has demonstrated multi-log viral load reductions across the breadth of viral families that MDL-001 inhibits."
Kris White Ph.D
"This is an exciting next-generation oral SARS-CoV-2 and broad-spectrum antiviral therapeutic candidate."

Adolfo Garcia-Sastre, Ph.D
"A game-changer in the global fight against COVID-19."
Launa Aspeslet, Ph.D
"Model Medicines is one of the few companies that have achieved both platform and therapeutic success."
Davey Smith, MD, MAS, FACP, FIDSA
"We need a pan-antiviral drug like MDL-001 to protect ourselves and our communities from the triple threat of RSV, flu, and COVID-19."
Philippe A. Gallay, Ph.D
"There has never been an orally available antiviral that has demonstrated multi-log viral load reductions across the breadth of viral families that MDL-001 inhibits."
Kris White Ph.D
"This is an exciting next-generation oral SARS-CoV-2 and broad-spectrum antiviral therapeutic candidate."

Adolfo Garcia-Sastre, Ph.D
"A game-changer in the global fight against COVID-19."
Launa Aspeslet, Ph.D
"Model Medicines is one of the few companies that have achieved both platform and therapeutic success."
Davey Smith, MD, MAS, FACP, FIDSA
"We need a pan-antiviral drug like MDL-001 to protect ourselves and our communities from the triple threat of RSV, flu, and COVID-19."
Philippe A. Gallay, Ph.D
"There has never been an orally available antiviral that has demonstrated multi-log viral load reductions across the breadth of viral families that MDL-001 inhibits."
Kris White Ph.D
"This is an exciting next-generation oral SARS-CoV-2 and broad-spectrum antiviral therapeutic candidate."

Newsroom

Get the latest updates on press releases and other announcements

Press Coverage

May 15, 2026

Fierce Biotech Profiles Model Medicines’ “Creative Models” for AI Drug Discovery

Model Medicines presentation on end-to-end AI drug discovery at Fierce Biotech Week 2026

Events

May 14, 2026

Model Medicines to Present End-to-End AI Drug Discovery Platform at Fierce Biotech Week 2026 in Boston

Model Medicines 325-billion-molecule virtual screening presentation at ACE Drug Discovery Summit

Events

May 6, 2026

Model Medicines to Present 325-Billion-Molecule Ultra-Large Virtual Screening at 7th ACE Drug Discovery Summit in San Diego

Press Coverage

May 15, 2026

Fierce Biotech Profiles Model Medicines’ “Creative Models” for AI Drug Discovery

Events

May 14, 2026

Model Medicines to Present End-to-End AI Drug Discovery Platform at Fierce Biotech Week 2026 in Boston

Events

May 6, 2026